C4 Therapeutics, Inc.

Alexander W Hird

Christopher G Nasveschuk

Kiel Lazarski

Georg Jaeschke

Yanke Liang

Daniel Rueher

Martin Duplessis

Annick Goergler

Jae Young Ahn

Antonio Ricci

Ryan E Michael

Ning Yin

Gesine Kerstin Veits

Hongwei Huang

Scott Joseph Eron

Andrew Charles Good

The invention provides compounds that degrade the epidermal growth factor receptor (EGFR) including mutant forms via the ubiquitination of the EGFR protein and subsequent proteasomal degradation. The compounds are useful for the treatment of various cancers.

Isoindolinone and indazole compounds for the degradation of EGFR

This invention provides Degron compounds which bind to cereblon which is a component of the E3 ubiquitin ligase. The Degrons provided herein can be used to modulate the activity of cereblon either alone or as covalently linked to a Tail. Alternatively, the Degron can be linked to a Targeting Ligand which binds to a Target Protein for protein degradation.

Bicyclic-substituted glutarimide cereblon binders

Growing community of inventors

Belmont, MA, United States of America

Alexander W Hird